On February 12, the reporter learned that the College of American Pathologists (CAP) recently announced the capability verification results of ngshm-b in 2021. Shanghai Rightongene Biotechnology Co.Ltd(688217) Wuhan siteide clinical testing laboratory passed this ability verification with full marks. This indicates that the detection ability of NGS technology in Shanghai Rightongene Biotechnology Co.Ltd(688217) clinical testing laboratory in blood tumors has been recognized by international authoritative institutions.
The data show that ngshm-b project is an evaluation project used by cap to evaluate the ability of the global gene testing laboratory to detect gene variation of blood tumors based on ngs technology. This test involves a total of 114 loci of 19 genes such as ASXL1, all of which are mutation sites with high frequency and extremely important clinical significance in blood tumors. Shanghai Rightongene Biotechnology Co.Ltd(688217) the test results are completely consistent with the published standard of cap. All mutation sites are detected, and the sensitivity and specificity are 100%.
